Patents Issued in July 25, 2019
  • Methods of Treatment of Hypertriglyceridemia
    Publication number: 20190224169
    Abstract: The present invention relates to pharmacological interventions with pemafibrate for moderate or severe hypertriglyceridemia.
    Type: Application
    Filed: December 20, 2018
    Publication date: July 25, 2019
    Inventors: Ryu Oshima, Kazuhito Suehira, Gary Gordon
  • THERAPIES AND METHODS TO TREAT INFLAMMATORY GASTROINTESTINAL DISEASES AND DISORDERS
    Publication number: 20190224170
    Abstract: The disclosure provides for therapies and methods to treat inflammatory gastrointestinal diseases and disorders with compositions that comprise therapeutically effective amounts of a biotin-based compound and/or a pantothenic acid-based compound.
    Type: Application
    Filed: January 23, 2019
    Publication date: July 25, 2019
    Inventor: Hamid M. Said
  • LIQUID RIZATRIPTAN COMPOSITIONS
    Publication number: 20190224171
    Abstract: The present invention is directed to liquid rizatriptan compositions. The present invention is further directed to methods of treating migraines comprising administering a liquid rizatriptan composition to a subject in need thereof.
    Type: Application
    Filed: January 18, 2019
    Publication date: July 25, 2019
    Inventors: Ravi Vaishya, Huaguang Li, Oscar Liu, Venkat R. Goskonda
  • COMPOUNDS AND METHODS FOR TREATING LUPUS
    Publication number: 20190224172
    Abstract: Methods for treatment of systemic lupus erythematosus (SLE” or “Lupus”) by administration of a modulator of sphingosine-1-phosphate receptor subtype 1 (S1P1), as well as compositions and methods related to the same, wherein such S1P1 modulators have the following general structure and wherein X and Y are as defined herein.
    Type: Application
    Filed: September 28, 2017
    Publication date: July 25, 2019
    Inventors: Fiona Lorraine Scott, Kristen R. Taylor Meadows, Robert Peach
  • COMPOSITIONS FOR AN ORALLY ACTIVE 1,2,4-OXADIAZOLE FOR THE TREATMENT OF DISEASE
    Publication number: 20190224173
    Abstract: The present invention relates to specific doses of and dosing regimens for using a 1,2,4-oxadiazole benzoic acid compound in treating or preventing diseases associated with nonsense mutations. In particular, the invention relates to specific doses and dosing regimens for the use of 3-[5-(2-fluoro-phenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acid in mammals having diseases associated with nonsense mutations.
    Type: Application
    Filed: March 29, 2019
    Publication date: July 25, 2019
    Inventors: Samit Hirawat, Langdon Miller
  • COMPOUNDS FOR TREATING DISEASES ASSOCIATED WITH A MITOCHONDRIAL DYSFUNCTION
    Publication number: 20190224174
    Abstract: The present invention relates to a compound of the following formula (A): or a pharmaceutically acceptable salt or hydrate thereof, for use in the prevention or treatment of a disease associated with a mitochondrial dysfunction.
    Type: Application
    Filed: August 30, 2017
    Publication date: July 25, 2019
    Inventors: ANTOINE DANCHIN, AGNIESZKA SEKOWSKA, PATRICE GARNIER
  • SOLID DISPERSION FORMS OF RIFAXIMIN
    Publication number: 20190224175
    Abstract: Provided herein are solid dispersions comprising rifaximin and pharmaceutical compositions and uses thereof.
    Type: Application
    Filed: March 29, 2019
    Publication date: July 25, 2019
    Inventors: Pam Golden, Mohammed A. Kabir
  • COMBINATION CONTAINING SGC ACTIVATORS AND MINERALOCORTICOID RECEPTOR ANTAGONISTS
    Publication number: 20190224176
    Abstract: The present invention relates to the combination of activators of soluble guanylate cyclase (sGC activators) with mineralocorticoid receptor antagonists (MR antagonists) and to the use of the combination for the treatment and/or prophylaxis of cardiac and cardiovascular disorders, of renal and cardiorenal disorders, of pulmonary and cardiopulmonary disorders and also for the treatment and/or prophylaxis of fibrotic disorders.
    Type: Application
    Filed: October 5, 2017
    Publication date: July 25, 2019
    Applicant: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Peter KOLKHOF, Peter SANDNER
  • STABLE LIQUID COMPOSITIONS OF SODIUM PICOSULFATE
    Publication number: 20190224177
    Abstract: A stable pharmaceutical liquid composition of sodium picosulfate, magnesium oxide, citric acid, comprising one or more stabilizers selected from organic acid or its derivatives thereof selected from maleic acid, sodium gluconate, formic acid, sodium alginate, oxalic acid; ammonium chloride or a combination thereof is provided. The present invention also relates to process of making and using such a composition.
    Type: Application
    Filed: December 10, 2018
    Publication date: July 25, 2019
    Inventors: Bharat Kirthivasan, Sabarinath Shankar, James Garegnani, Arjun Muthukkaruppan
  • ALTERING EXPRESSION LEVEL OF GLUTATHIONE S-TRANSFERASE GENES BY TREATING A HUMAN SUBJECT WITH A NITROXIDE
    Publication number: 20190224178
    Abstract: A method of treatment is disclosed. The method comprises administering to a human subject, known to have decreased glutathione activity, an effective amount of a nitroxide antioxidant, wherein the nitroxide antioxidant increases an expression level of one or more genes encoding glutathione S-transferase enzymes, thereby increasing glutathione activity.
    Type: Application
    Filed: January 19, 2018
    Publication date: July 25, 2019
    Inventor: Louis Habash
  • DECREASING EXPRESSION LEVEL OF PROTEASOME SUBUNIT GENES BY TREATING A HUMAN SUBJECT WITH A NITROXIDE
    Publication number: 20190224179
    Abstract: Some embodiments disclosed herein include a method for decreasing gene expression of a gene. The methods can include identifying a human subject over the age of 35 and having an increase expression level of a gene associated with proteasome activity; and administering to the human subject an effective amount of a nitroxide antioxidant, whereby expression level of the gene is decreased.
    Type: Application
    Filed: January 22, 2018
    Publication date: July 25, 2019
    Inventor: Louis Habash
  • Non-Aqueous Liquid Nimodipine Compositions
    Publication number: 20190224180
    Abstract: Non-aqueous liquid compositions comprising nimodipine having improved stability over aqueous compositions comprising nimodipine are provided herein. Methods of improving neurological outcome by reducing the incidence and severity of ischemic deficits in patients with subarachnoid hemorrhage from ruptured intracranial berry aneurysms with the non-aqueous liquid compositions of the present invention are also detailed herein.
    Type: Application
    Filed: April 16, 2018
    Publication date: July 25, 2019
    Inventor: Hugh Greg Thomas
  • TOPICAL RETINOID COMPOSITIONS
    Publication number: 20190224181
    Abstract: The present application relates to topical compositions. In particular, the present application relates to a topical composition comprising retinoid as active agent, and pharmaceutically acceptable excipient(s), and a process of preparing such compositions. Further, the present application relates to method of using topical compositions for the treatment of skin disorders such as acne, rosacea, psoriasis etc.
    Type: Application
    Filed: March 29, 2019
    Publication date: July 25, 2019
    Inventors: Sateesh Kandavilli, Franklin Okumu, Manish M. Bankar, Sujit Kumar Dolai
  • HAIR FOLLICLE STEM CELL ACTIVATION AND HAIR GROWTH
    Publication number: 20190224182
    Abstract: There are provided, inter alia, methods and compounds and method for inducing hair growth in a subject in need thereof.
    Type: Application
    Filed: August 25, 2017
    Publication date: July 25, 2019
    Inventor: William Lowry
  • Methods of Managing Conditioned Fear with Neurokinin Receptor Antagonists
    Publication number: 20190224183
    Abstract: This disclosure relates to managing conditioned fear and conditions induced by experiencing or witnessing an extreme traumatic event using neurokinin receptor antagonists. In certain embodiments, the disclosure relates to methods of treating or preventing conditioned fear comprising administering an effective about neurokinin 3 receptor antagonist to a subject in need thereof. In certain embodiments, the subject is diagnosed with Post-Traumatic Stress Disorder.
    Type: Application
    Filed: March 29, 2019
    Publication date: July 25, 2019
    Inventors: Kerry J. Ressler, Raul Andreo Gali
  • PREPARATION OF (-)-COCAINE HYDROCHLORIDE
    Publication number: 20190224184
    Abstract: Efficient methods are provided for large scale production of ethyl cocaine-free cocaine hydrochloride. Compositions and methods comprising administration of cocaine hydrochloride are provided.
    Type: Application
    Filed: May 16, 2018
    Publication date: July 25, 2019
    Inventors: Qingwei Yao, Se-Ho Kim
  • PREPARATION OF (-)-COCAINE HYDROCHLORIDE
    Publication number: 20190224185
    Abstract: Efficient methods are provided for large scale production of ethyl cocaine-free cocaine hydrochloride. Compositions and methods comprising administration of cocaine hydrochloride are provided.
    Type: Application
    Filed: November 13, 2018
    Publication date: July 25, 2019
    Inventors: Qingwei Yao, Se-Ho Kim
  • TREATMENT OF MULTIPLE SCLEROSIS WITH CHS-131
    Publication number: 20190224186
    Abstract: Methods of treatment of multiple sclerosis (MS) in humans, and in women in particular, comprising administering CHS-131 of the following formula: (I) or a pharmaceutically acceptable salt, prodrug or isomer of CHS-131.
    Type: Application
    Filed: September 13, 2017
    Publication date: July 25, 2019
    Inventors: Barbara Finck, Robert Zivadinov, Hong Tang
  • NEW USE OF ISOQUINOLINE DERIVATIVES FOR WOUND HEALING
    Publication number: 20190224187
    Abstract: The present invention is related to a method for wound healing comprising administering to a subject in need thereof a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound having the general Formula I, preferably salsolinol.
    Type: Application
    Filed: January 22, 2019
    Publication date: July 25, 2019
    Applicant: ZIH YUAN TANG Biotechnology Co., Ltd
    Inventors: Ming-Jai SU, Shoei-Sheng LEE, Chao-Min HSU
  • SUBSTITUTED HETEROCYCLES AS ANTIVIRAL AGENTS
    Publication number: 20190224188
    Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts thereof: which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
    Type: Application
    Filed: January 18, 2019
    Publication date: July 25, 2019
    Inventors: Joseph Panarese, Samuel Bartlett, Katherine Chong, Yat Sun Or
  • USE OF TYROSINE-KINASE INHIBITOR IN PREPARING PHARMACEUTICAL PRODUCT FOR CANCER TREATMENT
    Publication number: 20190224189
    Abstract: Provided is a method of treating cancer with a tyrosine-kinase inhibitor. In particular, provided is a method of treating cancer containing a mutated epidermal growth factor receptor (EGFR) with compound A, or a pharmaceutically acceptable salt thereof, preferably a maleate or dimaleate salt of compound A.
    Type: Application
    Filed: September 22, 2017
    Publication date: July 25, 2019
    Inventors: Jianjun ZOU, Yaling HUANG, Tonghuan HU, Xiaoyu ZHU, Jun FENG, Changyong YANG, Chen ZONG, Guoqing CAO
  • PYRIDINYL AND FUSED PYRIDINYL TRIAZOLONE DERIVATIVES
    Publication number: 20190224190
    Abstract: Disclosed are compounds of Formula 1, or pharmaceutically acceptable salts thereof, wherein R1, R2, R3, and R4 are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula 1, to pharmaceutical compositions which contain them, and to their use for treating Type I hypersensitivity reactions, autoimmune diseases, inflammatory disorders, cancer, non-malignant proliferative disorders, and other conditions associated with BTK.
    Type: Application
    Filed: April 3, 2019
    Publication date: July 25, 2019
    Inventors: John David Lawson, Mark Sabat, Nicholas Scorah, Christopher Smith, Phong H. Vu, Haixia Wang
  • MECLOZINE DERIVATIVES AND DICLAZURIL DERIVATIVES FOR USE IN THE PREVENTION AND/OR THE TREATMENT OF DISORDERS ASSOCIATED TO THE INFLAMMATION INDUCED BY P. ACNES
    Publication number: 20190224191
    Abstract: The present invention relates to compounds of the following general formula (I) or (II) or a pharmaceutically acceptable salt and/or solvate thereof, for use in the prevention and/or the treatment of disorders associated to the inflammation induced by P. acnes, in particular in the prevention and/or the treatment of acne, psoriasis, chronic urticaria, urticaria pigmentosa, cutaneous autoinflammatory diseases, hidradenitis or atopic dermatis.
    Type: Application
    Filed: July 13, 2017
    Publication date: July 25, 2019
    Applicants: Universite Paris Descartes, Assistance Publique - Hopitaux de Paris, Institut National de la Sante et de la Recherche Medicale (INSERM), Centre National de la Recherche Scientifique (CNRS), Sorbonne Universite
    Inventors: Nicolas Dupin, Vincent Calvez, Philippe Grange, Anne-Geneviève Marcelin
  • Stable Pharmaceutical Composition of Vortioxetine Hydrobromide
    Publication number: 20190224192
    Abstract: The present invention relates to novel premixes of Vortioxetine, processes for the preparation of such premixes, pharmaceutical compositions comprising the same and their use in medicine.
    Type: Application
    Filed: August 29, 2017
    Publication date: July 25, 2019
    Inventors: Geena MALHOTRA, Dharmaraj Ramachandra RAO, Venkata Srinivas PULLELA, Preeti RAUT, Shrikant Suresh MUDGAL, Pratap Ramesh SAWANT, Jinesh CHAUHAN, Nidhi BAGREE
  • Compositions of Natural Extracts and Use Thereof in Methods for Preventing or Treating Diseases
    Publication number: 20190224193
    Abstract: A composition for reducing miR-3120 expression in a cell or tissue of a subject comprises at least one oil or extract selected from a group comprising an orange, frankincense and cannabis oil or extract. A method for reducing miR-3120 expression in a cell or tissue of a subject comprises administering to the subject a composition comprising at least one oil or extract selected from the group comprising an orange, frankincense and cannabis oil or extract.
    Type: Application
    Filed: September 18, 2018
    Publication date: July 25, 2019
    Inventor: Christopher Brian REID
  • COMPOSITION FOR TREATING OCULAR DISEASES AND METHODS OF USAGE AND MAKING
    Publication number: 20190224194
    Abstract: The disclosure generally relates to methods of treating an ocular disease, comprising administering an effective amount of a pharmaceutical composition to an eye of a subject in need thereof, wherein the pharmaceutical composition comprises nintedanib, or its salt, derivative, analog or polymorph, or combination thereof. The disclosure also relates to pharmaceutical composition or formulation, which can be used for treating ocular diseases. In another aspect, the disclosure provides method of making the pharmaceutical composition or formulation.
    Type: Application
    Filed: May 19, 2017
    Publication date: July 25, 2019
    Applicant: REYOUNG (SUZHOU) BIOLOGY SCIENCE & TECHNOLOGY CO., LTD.
    Inventors: Shuhua GUO, Jiewen ZHONG, Xinting YUAN, Zongren YAO
  • Oral Capsule Composite Formulation of Dutasteride and Tadalafil
    Publication number: 20190224195
    Abstract: The present invention relates to a capsule composite formulation comprising dutasteride represented by formula I, tadalafil represented by formula II, a fatty acid ester derivative having 8 to 10 carbon atoms, and a polysorbate- or polyoxylglyceride-based surfactant wherein both the two drugs are dissolved.
    Type: Application
    Filed: September 27, 2017
    Publication date: July 25, 2019
    Inventors: Taegon Baik, Seyeon Kim, Ju-Hee Kim, Seung Han Song, Young-Joon Park, Kyung Mi Park
  • TREATMENT OF PROSTATE CANCER
    Publication number: 20190224196
    Abstract: Methods for treating prostate cancer, including advanced prostate cancer, in a subject in need thereof, include administering once-daily to the subject, at least 80 mg of N-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-N?-methoxyurea, or a corresponding amount of a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: March 29, 2019
    Publication date: July 25, 2019
    Inventors: Vijaykumar Reddy RAJASEKHAR, Brendan Mark JOHNSON, David B. MacLEAN, Lynn SEELY, Paul N. MUDD, Jr.
  • SUBSTITUTED AMINOPYRIMIDINE COMPOUNDS AND METHODS OF USE
    Publication number: 20190224197
    Abstract: The invention relates to the preparation and use of new aminopyrirnidine derivatives as drug candidates in free form or in pharmaceutically acceptable salt form and formulations thereof for the modulation of a disorder or disease which is mediated by the activity of the PI3K enzymes The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of disorders or diseases, such as disorders of immunity and inflammation in which PI3K enzymes play a role in leukocyte function, and hyperproliferative disorders associated with PI3K activity, including but not restricted to leukemias and solid tumors, in mammals, especially humans.
    Type: Application
    Filed: January 18, 2019
    Publication date: July 25, 2019
    Applicants: Sunshine Lake Pharma Co., Ltd., Calitor Sciences, LLC
    Inventors: Ning Xi, Liang Wang, Xuejin Feng, Min Liao
  • CAP-DEPENDENT ENDONUCLEASE INHIBITORS
    Publication number: 20190224198
    Abstract: Provided is a compound of Formula (I) below, or a pharmaceutically acceptable salt, metabolite, or prodrug thereof: wherein: A1 is CR4 or N; A2 is CR5R6 or NR7; A3 is CR5?R6? or NR7?; each of R1, R2, R2?, R3, R3?, R4, R5, R5?, R6, R6?, R7, and R7?, independently, is hydrogen, deuterium, halogen, cyano, hydroxyl, carboxyl, amino, formyl, nitro, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 alkoxy, C2-6 alkenyloxy, C1-6 alkylcarbonyl, C1-6 alkyloxycarbonyl, C1-6 alkylamine, C3-20 carbocyclyl, or C3-20 heterocyclyl; or R5 and R6, R5? and R6?, or R5 and R5?, together with the adjacent atom to which they are each attached, form C3-10 carbocyclyl or C3-10 heterocyclyl. Further provided are a method of using the above-described compound, or the pharmaceutically acceptable salt, metabolite, or prodrug thereof for treating influenza and a pharmaceutical composition containing same.
    Type: Application
    Filed: January 18, 2019
    Publication date: July 25, 2019
    Inventors: Chu-Chung Lin, Hung-Chuan Chen, Chiayn Chiang, Chi-Feng Yen, Ming-Chu Hsu
  • MELANIN PRODUCTION INHIBITOR, WHITENING AGENT, FIBROBLAST ACTIVATOR, COLLAGEN AND/OR ELASTIN PRODUCTION PROMOTER AND WRINKLE AMELIORANT
    Publication number: 20190224199
    Abstract: The present invention provides an agent containing an orotic acid derivative that has high solubility in solvent and has superior physiological activity. The agent of the present invention is a melanin production inhibitor, whitening agent, fibroblast activator, collagen and/or elastin production promoter or wrinkle ameliorant containing as an active ingredient thereof an orotic acid derivative represented by the following general formula (1) or a salt thereof. In formula (1), R preferably represents a side chain of glutamic acid, glycine, histidine or aspartic acid. [In formula (1), R represents a side chain of a naturally-occurring amino acid and R may form, together with a nitrogen atom adjacent thereto through a single carbon atom, a hetero ring.
    Type: Application
    Filed: June 8, 2017
    Publication date: July 25, 2019
    Applicant: SHOWA DENKO K.K.
    Inventors: Daisuke YAGYU, Yuko NAKAGAMI, Ryota NIIBAYASHI, Eiko KATO
  • COMBINATIONS FOR THE TREATMENT OF CANCER
    Publication number: 20190224200
    Abstract: The present disclosure relates to certain combinations for the treatment of cancer in a subject, comprising one or more inhibitors of Tyro3, Axl, Mer, or c-Met, together with one or more compounds that are inhibitors of programmed cell death protein 1 (PD-1) or programmed death-ligand 1 (PD-L1).
    Type: Application
    Filed: August 22, 2017
    Publication date: July 25, 2019
    Applicant: IGNYTA, INC.
    Inventors: Eric Santos MARTIN, Yumi YOKOYAMA
  • PHARMACEUTICAL COMPOSITION COMPRISING NEPTINIB OR SALT THEREOF AND METHOD FOR CONTROLLING IMPURITY THEREOF
    Publication number: 20190224201
    Abstract: A pharmaceutical composition including neptinib is provided. The composition includes neptinib or a pharmaceutically acceptable salt thereof, and an excipient at a low risk of compatibleness. Furthermore, the pharmaceutical composition of the present invention may also include pharmaceutically acceptable organic acid or inorganic acid as a stabilizer. The content of impurity A maintains a non-significant increase in the long-term and accelerated stability investigation for the pharmaceutical composition.
    Type: Application
    Filed: September 1, 2017
    Publication date: July 25, 2019
    Inventors: Jingan YANG, Zhiguo WANG, Jing CUI, Xiaorou LIU
  • STABLE LIQUID FORMULATIONS OF PEMETREXED
    Publication number: 20190224202
    Abstract: The present invention provides a stable ready to use liquid parenteral formulations of Pemetrexed or a pharmaceutically acceptable salt thereof. Further this invention also describes process of preparing such formulations.
    Type: Application
    Filed: June 9, 2016
    Publication date: July 25, 2019
    Applicant: LEIUTIS PHARMACEUTICALS PVT. LTD.
    Inventors: Kocherlakota CHANDRASHEKHAR, Banda NAGARAJU
  • Methods of Treating Steroid Resistant Diseases and Conditions
    Publication number: 20190224203
    Abstract: Disclosed herein are methods treating and identifying a subject having a steroid resistant disease or condition.
    Type: Application
    Filed: January 23, 2019
    Publication date: July 25, 2019
    Inventor: Rafeul Alam
  • PHARMACEUTICAL COMPOSITIONS OF IBRUTINIB
    Publication number: 20190224204
    Abstract: This invention relates to novel pharmaceutical formulations of Bruton's tyrosine kinase (BTK) inhibitor Ibrutinib. This invention also relates to methods of using the Ibrutinib pharmaceutical formulations, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, cancers, including lymphoma, and inflammatory diseases or conditions.
    Type: Application
    Filed: August 19, 2017
    Publication date: July 25, 2019
    Inventors: Geena Malhotra, Jinesh Chauhan, Kishore Kothule, Ravichandra Bhadravathi Vedamurthy, Anirban Mallik Thakur
  • COMPOSITIONS AND METHODS OF TREATING CANCER
    Publication number: 20190224205
    Abstract: The invention is directed to methods of treating cancer in subjects with a combination comprising a CCR2/5 dual antagonist, such as N-((1R,2S,5R)-5-(tert-butylamino)-2-((S)-3-(7-tert-butylpyrazolo[1,5-a][1,3,5]triazin-4-ylamino)-2-oxopyrrolidin-1-yl)cyclohexyl)acetamide; a monoclonal antibody, such as nivolumab; and/or chemotherapy.
    Type: Application
    Filed: January 22, 2019
    Publication date: July 25, 2019
    Inventors: Qihong Zhao, Joseph Fargnoli, Murali Gururajan, Susan Wee
  • METABOLITES OF BICTEGRAVIR
    Publication number: 20190224206
    Abstract: The present invention provides metabolites of the antiviral drug bictegravir, including compositions and salts thereof, which are useful in the prevention and/or treatment of HIV as well as analytical methods related to the administration of bictegravir.
    Type: Application
    Filed: January 18, 2019
    Publication date: July 25, 2019
    Inventors: Haolun Jin, Hyung-Jung Pyun, Bill J. Smith, Raju Subramanian, Jianhong Wang
  • MULTIFUNCTIONAL INHIBITORS OF MEK/PI3K AND mTOR/MEK/PI3K BIOLOGICAL PATHWAYS AND THERAPEUTIC METHODS USING THE SAME
    Publication number: 20190224207
    Abstract: Multifunctional inhibitors of mTOR, MEK, and PI3K and compositions containing the same are disclosed. Methods of using the multifunctional inhibitors in the treatment of diseases and conditions wherein inhibition of one or more of mTOR, MEK, and PI3K provides a benefit, like cancers, also are disclosed.
    Type: Application
    Filed: July 6, 2017
    Publication date: July 25, 2019
    Inventors: Brian D. Ross, Marcian Van Dort
  • PHARMACEUTICAL COMPOSITION FOR TREATING PREMATURE EJACULATION AND METHOD FOR TREATING PREMATURE EJACULATION
    Publication number: 20190224208
    Abstract: The present invention relates to a pharmaceutical composition for treating, preventing or improving premature ejaculation, which is taken on demand prior to sexual activity, the composition comprising clomipramine hydrochloride in an amount of 14 to 16 mg, preferably about 15 mg, as an active ingredient. More preferably, the composition of the present invention further comprises pregelatinized starch and sodium starch glycolate. The pharmaceutical composition of the present invention can provide rapid onset of efficacy, reduce a dissolution (absorption) deviation according to the patient's gastrointestinal pH conditions and minimize side effects.
    Type: Application
    Filed: April 4, 2019
    Publication date: July 25, 2019
    Applicant: CTC Bio, Inc.
    Inventors: Hong-Ryeol Jeon, Do-Woo Kwon, Bong-Sang Lee, Seong-Shin Kwak, Sun-Ahe Lee, Hyun-Jung Park, Jeong-Hwa Yoo
  • COMBINATION THERAPY OF TETRACYCLIC QUINOLONE ANALOGS FOR TREATING CANCER
    Publication number: 20190224209
    Abstract: The present invention provides methods, compositions, and combinations for treating cancer via combined use of a compound of formula I or a pharmaceutically acceptable salt, ester, solvate and/or prodrug thereof, wherein A, Q, n, m, R7, R8, V, X1, X2, X3, X4, X5, X6, and X7 are as defined herein, and at least one therapeutically active agents selected from immunotherapeutics, anticancer agents, and anti-angiogenics.
    Type: Application
    Filed: January 18, 2019
    Publication date: July 25, 2019
    Inventor: John Soong
  • HETEROCYCLIC COMPOUNDS AND THEIR USE IN PREVENTING OR TREATING BACTERIAL INFECTIONS
    Publication number: 20190224210
    Abstract: A compound of formula (I) or a racemate, an enantiomer, a diastereoisomer, a geometric isomer or a pharmaceutically acceptable salt thereof, and its use as antibacterial agent.
    Type: Application
    Filed: September 29, 2017
    Publication date: July 25, 2019
    Inventors: Julien BARBION, Audrey CARAVANO, Sophie CHASSET, Francis CHEVREUIL, Fabien FAIVRE, Rémi LEBEL, Nicolas LECOINTE, Benoît LEDOUSSAL, Frédéric LE-STRAT, Christophe SIMON, Chrystelle OLIVEIRA, Géraldine LE FRALLIEC, Julie BRIAS, Laurence FARESCOUR, Sophie VOMSCHEID, Sébastien RICHARD
  • DEVICES AND METHODS OF TREATING METHAMPHETAMINE ADDICTION AND MEDICAL AND BEHAVIORAL CONSEQUENCES OF METHAMPHETAMINE USE AND OF HIV INFECTION
    Publication number: 20190224211
    Abstract: A method of treating a condition of in a human patient comprising pharmacologically activating a translocator protein of 18 kDa (TSPO), wherein the condition is one of a chronic methamphetamine addiction, a medical consequence of methamphetamine use; a behavioral consequence of methamphetamine use, an HIV associated cognitive motor disorder, an HIV-associated neurodegenerative disorder, and a neuroinflammatory response.
    Type: Application
    Filed: June 4, 2018
    Publication date: July 25, 2019
    Inventors: Nicholas E. GOEDERS, Christopher Dalton SCHMOUTZ
  • Nrf2 REGULATORS
    Publication number: 20190224212
    Abstract: The present invention relates to aryl analogs, pharmaceutical compositions containing them and their use as NRF2 regulators.
    Type: Application
    Filed: April 4, 2019
    Publication date: July 25, 2019
    Inventors: Jeffrey K. Kerns, James Francis Callahan, Hongxing Yan, Thomas Daniel Heightman, Jeffrey Charles Boehm, Alison Jo-Anne Woolford
  • VAGINAL COMPOSITION COMPRISING A COMBINATION OF ESTROGEN AND VITAMIN D
    Publication number: 20190224213
    Abstract: The invention relates to vaginal composition comprising a combination of estrogen and vitamin D or a vitamin D analog at a daily dosage delivery of (i) estrogen ranging from 1 ?g to 100 ?g estrogen of estradiol equivalent and (ii) vitamin D or analog ranging from 7.5 ?g to 100 ?g of vitamin D equivalent.
    Type: Application
    Filed: July 20, 2017
    Publication date: July 25, 2019
    Applicant: Chemo Research S.L..
    Inventors: Enrico COLLI, David F. ARCHER
  • HUMAN GHRELIN O-ACYLTRANSFERASE INHIBITORS
    Publication number: 20190224214
    Abstract: A class of cyanosteroid compounds that efficiently inhibit ghrelin acylation by ghrelin O-acyltransferase. The compounds have a steroid scaffold with ?,?-unsaturated ketone in the A ring position such an ?-cyanoenone. Exemplary compounds include (5S,8S,9S,10S,13S,14S)-10,13-dimethyl-3-oxo-4,5,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-3H-cyclopenta[a]phenanthrene-2-carbonitrile.
    Type: Application
    Filed: August 15, 2017
    Publication date: July 25, 2019
    Applicant: SYRACUSE UNIVERSITY
    Inventors: James L. Hougland, John D. Chisholm
  • NEEDLE ASSISTED JET INJECTION ADMINISTRATION OF TESTOSTERONE COMPOSITIONS
    Publication number: 20190224215
    Abstract: The present invention provides compositions and methods for treating a subject in need of treatment with testosterone, including introducing testosterone into the subject subcutaneously, intradermally, or intramuscularly, from a needle assisted jet injection device.
    Type: Application
    Filed: February 1, 2019
    Publication date: July 25, 2019
    Applicant: Antares Pharma, Inc.
    Inventors: Paul K. Wotton, Hermanus L. Jooste, Kaushik J. Dave, Jonathan Jaffe
  • COMPOSITIONS COMPRISING ACIDIC EXTRACTS OF MASTIC GUM AND USES THEREOF FOR TREATING OPTIC NEUROPATHY
    Publication number: 20190224216
    Abstract: The invention relates to compositions and formulations comprising isolated acidic fraction of mastic gum and uses thereof for treating optic neuropathy conditions.
    Type: Application
    Filed: September 7, 2017
    Publication date: July 25, 2019
    Applicant: REGENERA PHARMA LTD.
    Inventors: Zadik HAZAN, Andre C. B. LUCASSEN, Konstantin ADAMSKY
  • COMPOSITIONS COMPRISING TRITERPENOIDS AND USES THEREOF FOR TREATING OPTIC NEUROPATHY
    Publication number: 20190224217
    Abstract: The invention relates to compositions and formulations comprising at least one triterpenoic acid and at least one neutral triterpenoid and uses thereof for treating optic neuropathy conditions.
    Type: Application
    Filed: September 7, 2017
    Publication date: July 25, 2019
    Applicant: REGENERA PHARMA LTD.
    Inventors: Zadik HAZAN, Andre C. B. LUCASSEN, Konstantin ADAMSKY
  • CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS
    Publication number: 20190224218
    Abstract: Chemical entities that are bufalin derivatives, pharmaceutical compositions and methods of treatment of cancer are described.
    Type: Application
    Filed: October 31, 2018
    Publication date: July 25, 2019
    Inventor: Xiangping Qian